Puma Biotechnology (PBYI) Insider Stuglik Sells $58K of Stock
Brian Stuglik offloaded 8,100 shares of Puma Biotechnology, Inc. on June 12, 2026, amid a coordinated group of planned sales by company insiders.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brian Stuglik sold 8,100 shares of Puma Biotechnology, Inc. ($PBYI) at an average price of $7.20, worth about $58,320, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $PBYI is up 4.5% after 1 week, up 10.2% after 1 month and up 34.1% to date (from the $7.33 close on Jun 12, 2026).
PBYI
Puma Biotechnology, Inc.
Key Points
- Puma Biotechnology, Inc. insider Brian Stuglik sold 8,100 shares of PBYI stock on June 12, 2026, at a price of $7.20 per share for a total value of $58,320.
- The transaction was part of a larger group of executive sales on the same day, which also included planned offloads by Wilson Troy Edward, Jay Moyes, and Adrian Senderowicz.
- TD Cowen recently maintained a hold rating on the stock on August 7, 2026, while raising its price target to $6.00.
Get $PBYI trade alerts by text
We text you when insiders, Congress or big funds trade $PBYI. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Puma Biotechnology, Inc. alert may contain errors. Disclosures
Brian Stuglik Executes Planned Stock Sale
Puma Biotechnology, Inc. insider Brian Stuglik parted with 8,100 shares of the biopharmaceutical firm on June 12, 2026. The transaction took place at a price of $7.20 per share, leading to a total value of $58,320. Regulatory disclosures show the move was carried out under a pre-arranged trading schedule.
Broad Wave of Executive Transactions
The sale by Stuglik was part of a larger group of insider transactions at the cancer-care product developer on June 12, 2026. Wilson Troy Edward disposed of 10,800 shares at $7.20 per share for a total of $77,760. Jay Moyes sold 22,000 shares at an average price of $7.22 per share, totaling $158,840. Adrian Senderowicz also participated by offloading 27,000 shares at $7.20 per share for a total value of $194,400. All of these transactions were arranged ahead of time.
Stock Valuation and Price Levels
The shares traded around $7.07 on Tuesday, resting close to the company's 200-day moving average of $7.28. Over the past year, the equity has moved between a low of $4.47 and a high of $9.75. The firm carries a market capitalization of approximately $495.0 million.
Analysts Set New Price Targets
Analyst coverage includes a recent update from TD Cowen on August 7, 2026. The firm maintained its hold rating on the stock while lifting its price target from $5.00 to $6.00.
Company Background and Operations
Puma Biotechnology, Inc. develops and commercializes products for cancer care in the United States and international markets. Its principal product is Nerlynx, an oral medication used for early-stage and advanced breast cancer. The enterprise also works on other oncology candidates through licensing deals with major pharmaceutical partners. Headquartered in Los Angeles, California, the company employs 179 people.
Upcoming Financial Reporting
Investors will look toward the company's next earnings report, which is scheduled for November 5, 2026, for further updates on commercial performance. Executive stock sales are common and often scheduled months in advance to satisfy personal financial planning goals rather than reacting to short-term news.
Related Filing Alerts
Source: Brian Stuglik's Form 4 filing on $PBYI (Jun 12, 2026). Find the original filing: PBYI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts